ExPEC: Who’s at Risk?

Read about the prevalence of infections caused by extraintestinal pathogenic Escherichia coli (ExPEC) and the populations at highest risk for invasive disease.
Lilian Abbo Headshot
Lilian Abbo, MD, FIDSA
Program Director
David Van Duin, MD, PhD, FIDSA, FAST
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 451 KB
Released: September 27, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Therapeutics, Division of Janssen Products, LP

Related Content

Expert faculty discuss ways to improve the empiric treatment of HABP/VABP in the ICU in this commentary from Clinical Care Options (CCO)

person default Marion Elligsen, BScPhm, MSc, RPh, ACPR Keith S. Kaye, MD, MPH Andrew Shorr, MD, MPH, MBA Released: November 18, 2022

Learn from experts about strategies to improve timely, effective antibiotic therapy in patients with HABP/VABP at risk for multidrug resistance, from Clinical Care Options (CCO)

Dr. Nneka Holder discusses strategies to improve meningococcal vaccine uptake in adolescent patients, from Clinical Care Options (CCO)

person default Nneka Holder, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: November 1, 2022 Expired: November 1, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings